

CLAIMS

1. A method of treating pancreatic cancer in a patient by administering to the patient an ATR inhibitor selected from




821




822

in combination with another cancer therapy selected from gemcitabine, radiation therapy, or both gemcitabine and radiation therapy together.

2. A method of increasing the sensitivity of pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy in a patient by administering to the patient an ATR inhibitor selected from



821




822


in combination with the cancer therapy.

3. The method of claim 1, wherein the cancer therapy is gemcitabine.
4. The method of claim 1, wherein the cancer therapy is radiation therapy.

5. A method of sensitizing hypoxic pancreatic cancer cells to a cancer therapy selected from gemcitabine or radiation therapy by administering to a patient an ATR inhibitor selected from




821




822

in combination with the cancer therapy.

6. A method of inhibiting phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell comprising administering to a patient an ATR inhibitor selected from




821




822

in combination with gemcitabine and/or radiation.

7. A method of radiosensitizing hypoxic pancreatic cancer cells by administering to a patient an ATR inhibitor selected from




821




822

in combination with radiation therapy.

8. A method of sensitizing hypoxic pancreatic cancer cells by administering to a patient an ATR inhibitor selected from




821




822

in combination with gemcitabine.

9. A method of sensitizing pancreatic cancer cells to chemoradiation by administering to a patient an ATR inhibitor selected from



821




822


in combination with chemoradiation.

10. The method of claim 9 wherein the chemotherapy is gemcitabine.

11. A method of disrupting damage-induced cell cycle checkpoints by administering to a patient an ATR inhibitor selected from




821




822

in combination with radiation therapy.

12. A method of inhibiting repair of DNA damage by homologous recombination in a pancreatic cancer cell by administering an ATR inhibitor selected from



821



822

in combination with radiation treatment.


13. The method of any one of claims 1-12, wherein the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.

14. The method of any one of claims 1-12, wherein the pancreatic cancer cells are in a cancer patient.


15. The method of any one of claims 1-12, wherein the compound is administered to a patient.

16. The method of any one of claims 1-12, wherein the compound is administered to a pancreatic cancer cell.

17. A method of treating non-small cell lung cancer in a patient comprising administering to the patient a compound of formula 821 or 822:



821



822

in combination with one or more of the following additional therapeutic agents: Cisplatin or Carboplatin, Etoposide, and ionizing radiation.

18. The method of claim 17, comprising administering to a patient a compound of formula 821 or 822 in combination with a cancer therapy selected from the group consisting of Cisplatin or Carboplatin, Etoposide, and ionizing radiation.

19. The method of claim 18, wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide.


20. The method of claim 18, wherein the cancer therapy is Cisplatin or Carboplatin and Etoposide and ionizing radiation.

21. The method of claim 18, wherein the cancer therapy is ionizing radiation.


22. The method according to any one of claims 1-21, wherein the ATR inhibitor is 822.

CLAIMS

1. A method of treating pancreatic cancer in a patient by administering to the patient an ATR inhibitor selected from



821



822

in combination with another cancer therapy selected from gemcitabine, radiation therapy, or both gemcitabine and radiation therapy together, wherein the pancreatic cancer cells are derived from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or Panc-1.